Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis

References

• Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428
   PubMed Web of Science ®Google Scholar
• Delmas PD, Marin F, Marcus R, et al. Beyond hip: importance of other nonspinal fractures. Am J Med 2007;120:381-387
   PubMed Web of Science ®Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-1767
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-339
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Johnell O, Cooper C, et al. Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int 2006;17:201-211
   PubMed Web of Science ®Google Scholar
• General guidelines for economic evaluations from the Pharmaceutical Benefits Board. (LFNAR 2003:2) [cited 2007 2007-05-12]. 2003; Available from http://www.lfn.se/LFNTemplates/Page____442.aspx
   Google Scholar
• Borgstrom F, Jonsson B, Strom O, et al. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 2006;17:1781-1793
   PubMed Web of Science ®Google Scholar
• Johnell O, Jonsson B, Jonsson L, et al. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003;21:305-314
   PubMed Web of Science ®Google Scholar
• TreeAge Pro 2007. User Manual TreeAge software inc 2007
   Google Scholar
• Rajzbaum G, Jakob F, Karras D, et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008;24:377-384
   PubMed Web of Science ®Google Scholar
• Ljunggren O, Toll A, Myren KJ, et al. Prescription pattern of human recombinant 1-34 parathyroid hormone (Teriparatide, Forsteosup>/sup>) in Sweden. Osteoporos Int 2006;17:S71-72
   Web of Science ®Google Scholar
• Behandling av Osteoporos - Rekommendationer. Läkemedelsverket (Medical Product Agency) [cited 2007-07-03]. 2007; Available from: http://www.lakemedelsverket.se/upload/Hälso-%20och%20sjukvård/behandlingsrek/osteoporos2007.pdf
   Google Scholar
• Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024-2030
   PubMed Web of Science ®Google Scholar
• Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20:1507-1513
   PubMed Web of Science ®Google Scholar
• Zethraeus N, Strom O, Borgstrom F. What is the risk of institutionalization after hip fracture? Osteoporos Int 2006;17:57-58
   Google Scholar
• Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:1645-1652
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 2000;11:669-674
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001;12:417-427
   PubMed Web of Science ®Google Scholar
• Melton III LJ, Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 1999;9:29-37
   PubMed Web of Science ®Google Scholar
• De Laet CE, van Hout BA, Burger H, et al. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997;315:221-225
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int 2004;15:175-179
   PubMedGoogle Scholar
• Statistics Sweden. Swedeńs Statistical Databases [cited 2007-05-30]. 2007; Available from: http://www.scb.se/eng/databaser/ssd.asp
   Google Scholar
• Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-561
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D, et al. after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-882
   PubMed Web of Science ®Google Scholar
• Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-1005
   PubMed Web of Science ®Google Scholar
• Jalava T, Sarna S, Pylkkanen L, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 2003;18:1254-1260
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004;15:108-112
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004;15:38-42
   PubMed Web of Science ®Google Scholar
• Poor G, Atkinson EJ, O'Fallon WM, et al. Determinants of reduced survival following hip fractures in men. Clin Orthop 1995;319:260-265
   PubMed Web of Science ®Google Scholar
• Parker MJ, Anand JK. What is the true mortality of hip fractures? Public Health 1991;105:443-446
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003;32:468-473
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004;15:20-26
   PubMed Web of Science ®Google Scholar
• Average Exchange Rates. Sveriges Riksbank [cited 2007-09-15]. 2007; Available from: http://www.riksbanken.com
   Google Scholar
• Farmaceutiska Specialiteter i Sverige (FASS). [cited 2007-10-31]. 2009; Available from: www.fass.se
   Google Scholar
• Summary of Product Characteristics. [cited 2007-12-01]. 2007; Available from: www.emea.europa.eu/humandocs/PDFs/EPAR/preotact/H-659-PI-en.pdf
   Google Scholar
• Borgstrom F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006;17:637-650
   PubMed Web of Science ®Google Scholar
• Strom O, Borgstrom F, Zethraeus N, et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 2008;79:269-280
   PubMed Web of Science ®Google Scholar
• Jonsson B, Christiansen C, Johnell O, et al. Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 1996;103:30-38
   PubMedGoogle Scholar
• Stockholms stads budgetavräkning 2003 [online]. [cited 2004-12-20]. 2009; Available from: www.stockholm.se/files/71600-71699/file_71645.pdf
   Google Scholar
• Borgstrom F, Strom O. Long-term hip fracture costs related to institutionalization. Osteoporos Int 2007;18(Suppl 1):S1-192. Osteoporos Int 2007;18:S1-192
   PubMed Web of Science ®Google Scholar
• Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006;166:1209-1217
   PubMed Web of Science ®Google Scholar
• Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997;16:33-64
   PubMed Web of Science ®Google Scholar
• Burstrom K, Johannesson M, Diderichsen F. population health-related quality of life results using the EQ-5D. Qual Life Res 2001;10:621-635
   PubMed Web of Science ®Google Scholar
• Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736-741
   PubMed Web of Science ®Google Scholar
• Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-340
   PubMed Web of Science ®Google Scholar
• The National Centre for Priority Setting in Health Care (PrioriteringsCentrum). Nationell model for öppna vertikala prioriteringar inom svensk hälso- och sjukvård. PrioriteringsCentrum 2007;1
   Google Scholar
• Sutton A, Ades AE, Cooper N, et al. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008;26:753-767
   PubMed Web of Science ®Google Scholar
• Briot K, Ravaud P, Dargent-Molina P, et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 2009;20:625-630
   PubMed Web of Science ®Google Scholar
• Adachi JD, Hanley DA, Lorraine JK, et al. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther 2007;29:2055-2067
   PubMed Web of Science ®Google Scholar
• Arden NK, Earl S, Fisher DJ, et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 2006;17:1626-1629
   PubMed Web of Science ®Google Scholar